TLSA — Tiziana Life Sciences Ltd
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1723069 ·
Last close
$1.51
Market Cap
$192.16M
52W High
$1.85
52W Low
$1.14
ADV30
217,501
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Dec 2025 | — | — | — | — | 11,495,000 | 4,010,000 | 11,443,000 |
| Dec 2024 | — | — | — | — | 11,284,000 | 3,724,000 | 7,348,000 |
Balance + Analyst (yfinance extras)
Retained Earnings
$-144,831,000
Inventory
—
Receivables
$3,692,000
ST Investments
—
EBIT TTM
—
Pretax Income TTM
—
Interest Exp TTM
—
Analysts
1
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -21,132,000 | -18,431,000 | 11,495,000 | 11,443,000 | — | -12,847,000 |
| Dec 2024 | 0 | -15,794,000 | -11,863,000 | 11,284,000 | 7,348,000 | — | -1,526,000 |
| Dec 2023 | 0 | -17,984,000 | -17,691,000 | 12,184,000 | 6,648,000 | — | -15,698,000 |
| Dec 2022 | 0 | -14,586,000 | -15,397,000 | 26,477,000 | 6,906,000 | — | -19,615,000 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.20
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ELTX | Elicio Therapeutics, Inc. | $191.43M | $10.03 | — |
| RNAC | Cartesian Therapeutics, Inc. | $189.51M | $6.45 | — |
| UNCY | Unicycive Therapeutics, Inc. | $188.50M | $7.06 | — |
| GALT | GALECTIN THERAPEUTICS INC | $183.74M | $2.79 | — |
| KPTI | Karyopharm Therapeutics Inc. | $203.29M | $8.97 | — |
News headlines (Yahoo Finance, 1h cache)
Tiziana Life Sciences advances foralumab program with full Phase 2 enrollment and encouraging expanded access data – ICYMI
2026-05-22 20:48 · Yahoo
Tiziana Life Sciences completes enrollment in Phase 2a multiple sclerosis trial
2026-05-21 15:44 · Yahoo
Tiziana Fully Enrolls its Phase 2 Placebo Controlled Multiple Sclerosis Trial
2026-05-21 15:00 · Yahoo
Sector Update: Healthcare Stocks Gain Late Afternoon
2026-05-19 19:55 · Yahoo
Tiziana Life Sciences price target boosted on foralumab update
2026-05-19 19:12 · Yahoo
Sector Update: Healthcare Stocks Rise Tuesday Afternoon
2026-05-19 18:02 · Yahoo
Tiziana Life Sciences reports encouraging one-year data for intranasal foralumab in progressive MS
2026-05-19 13:42 · Yahoo
Tiziana Announces New Positive Clinical Data for Intranasal Foralumab in Non-Active Secondary Progressive Multiple Sclerosis
2026-05-19 11:00 · Yahoo
Tiziana Reports Reduced Brain Inflammation in Multiple System Atrophy Patients Treated with Intranasal Foralumab
2026-05-14 11:00 · Yahoo
Inventiva Builds Up Leadership Team Ahead of Potential Commercialization
2026-04-22 22:03 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.